11/20
08:00 am
fhtx
Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies
Low
Report
Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies
11/20
06:30 am
fhtx
Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer
Low
Report
Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer
11/13
08:00 am
fhtx
Brian M. Alexander Joins Valo Health as Chief Executive Officer and Flagship Pioneering as CEO-Partner
Medium
Report
Brian M. Alexander Joins Valo Health as Chief Executive Officer and Flagship Pioneering as CEO-Partner
11/13
08:00 am
fhtx
Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio
Medium
Report
Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio
11/12
08:01 am
fhtx
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences [Yahoo! Finance]
11/12
07:54 am
fhtx
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
Medium
Report
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
11/7
08:47 am
fhtx
Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Third-Quarter Report [Yahoo! Finance]
Low
Report
Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Third-Quarter Report [Yahoo! Finance]
11/6
07:21 am
fhtx
We Think Foghorn Therapeutics (NASDAQ:FHTX) Needs To Drive Business Growth Carefully [Yahoo! Finance]
Low
Report
We Think Foghorn Therapeutics (NASDAQ:FHTX) Needs To Drive Business Growth Carefully [Yahoo! Finance]
11/4
06:59 pm
fhtx
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates [Yahoo! Finance]
Medium
Report
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates [Yahoo! Finance]
11/4
04:19 pm
fhtx
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update [Yahoo! Finance]
Medium
Report
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update [Yahoo! Finance]
11/4
04:05 pm
fhtx
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update
Medium
Report
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update
10/23
08:00 am
fhtx
Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence
Low
Report
Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence
10/10
07:00 am
fhtx
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors
Low
Report
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors
10/9
07:00 am
fhtx
Flagship Pioneering Announces Appointment of Paul Parker as Managing Partner, Leading Capital Solutions
Medium
Report
Flagship Pioneering Announces Appointment of Paul Parker as Managing Partner, Leading Capital Solutions
10/7
07:02 am
fhtx
BeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last? [Yahoo! Finance]
Low
Report
BeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last? [Yahoo! Finance]
10/3
08:00 am
fhtx
Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors
High
Report
Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors
10/2
09:00 pm
fhtx
A*STAR and Flagship Pioneering Announce Partnership to Spur Biotech Innovation in Singapore
High
Report
A*STAR and Flagship Pioneering Announce Partnership to Spur Biotech Innovation in Singapore
10/2
09:00 pm
fhtx
A*STAR and Flagship Pioneering Announce Partnership to Spur Biotech Innovation in Singapore
High
Report
A*STAR and Flagship Pioneering Announce Partnership to Spur Biotech Innovation in Singapore
10/1
07:00 am
fhtx
Foghorn Therapeutics to Participate in the BMO Oncology Summit
Medium
Report
Foghorn Therapeutics to Participate in the BMO Oncology Summit
9/26
06:00 am
fhtx
Flagship Pioneering Unveils Mirai Bio to Provide Fully Integrated End-to-End Genetic Medicine Development Capabilities for the Biotech Industry
Medium
Report
Flagship Pioneering Unveils Mirai Bio to Provide Fully Integrated End-to-End Genetic Medicine Development Capabilities for the Biotech Industry
9/24
08:09 am
fhtx
Foghorn Therapeutics Inc. (NASDAQ: FHTX) had its price target raised by analysts at Morgan Stanley from $6.00 to $9.00. They now have an "equal weight" rating on the stock.
Medium
Report
Foghorn Therapeutics Inc. (NASDAQ: FHTX) had its price target raised by analysts at Morgan Stanley from $6.00 to $9.00. They now have an "equal weight" rating on the stock.
9/16
06:09 am
fhtx
Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength? [Yahoo! Finance]
Medium
Report
Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength? [Yahoo! Finance]
9/3
08:03 am
fhtx
Foghorn Therapeutics Inc. (NASDAQ: FHTX) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $18.00 price target on the stock.
Medium
Report
Foghorn Therapeutics Inc. (NASDAQ: FHTX) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $18.00 price target on the stock.
9/3
07:00 am
fhtx
Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
Medium
Report
Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
8/28
07:00 am
fhtx
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September
Medium
Report
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September